Preface 3 The health sector, in particular the areas of medical technology, red biotechnology and the pharmaceutical industry, is one of the key areas and future-oriented technologies in Saxony-Anhalt.
Description of Arms: Principal Title: Duke of Anhalt. Creation: Holy Roman Empire, 1218. Subsidiary Titles: Duke of Saxony (1180), of Engernand Westphalia, Count of Ascania.
DIGITAL Landscape Architecture - Conference 2009 by Anhalt University - Programme Version 12 May, 2009 page 1 (of 4) DIGITAL LANDSCAPE ARCHITECTURE 2009 21- 23 May, Valletta, Malta WEDNESDAY, May 20 _____ 18:00 -22:00 Registration, technical set up for speakers, and ...
What makes Germany so attractive? Interview with Chief Economist of the Deutsche Bank, Prof. Norbert Walter Cooperation breeds success Focus on the emergence of a unique tech
FROM THE HEART OF GERMANY TO THE CENTRE OF EUROPE EU enlargement has moved Central Germany into the centre of the European economic area. Saxony-Anhalt, a high-perf ormance location in the Central German industrial region that boasts a long tradit ion, is gaining importance as a node of East ...
Building the DTM for the State of Saxony-Anhalt in Germany Steffen PATZSCHKE 1 Introduction This article describes the building of digital terrain models (DTM) in Saxony-Anhalt.
CONSENSUS STATEMENT: Childhood Obesity Phyllis W. Speiser, Mary C. J. Rudolf, Henry Anhalt, Cecilia Camacho-Hubner, Francesco Chiarelli, Alon Eliakim, Michael Freemark, Annette Gruters, Eli Hershkovitz, Lorenzo Iughetti, Heiko Krude,
Henry Anhalt, DO Chief Medical Officer and Medical Director, Artificial Pancreas Program Animas Corporation Dr. Henry Anhalt, Chief Medical Officer and Medical Director of the Artificial Pancreas Program for Animas Corporation is responsible for the company's medical and clinical activities.
67 Impressum: European Chemical Regions Network (ECRN) Ministry for Economy and Labour of the State of Saxony-Anhalt Hasselbachstraße 04 D-39104 Magdeburg Telephone: ...
SAXONY-ANHALT SUCCESS STORY | OCTOBER 2011 HEALING ASPIRIN FOR AN OLD PROBLEM REGION 20 years ago the Bayer Group decided to invest in Bitterfeld: today eight to nine billion tablets roll off the production lines each year.